Edesa Biotech Année d'introduction en bourse
Quel est le Année d'introduction en bourse de Edesa Biotech?
Le Année d'introduction en bourse de Edesa Biotech, Inc. est 2010
Quelle est la définition de Année d'introduction en bourse?
Le premier appel public à l'épargne est un type d'offre publique dans lequel les actions d'une entreprise sont généralement vendues à des investisseurs institutionnels qui, pour leur part, vendent au grand public, pour la première fois, sur une bourse de valeurs.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Année d'introduction en bourse des entreprises dans Health Care secteur sur NASDAQ par rapport à Edesa Biotech
Que fait Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Entreprises avec année d'introduction en bourse similaire à Edesa Biotech
- Chigo a Année d'introduction en bourse de 2009
- Jade Road Investments a Année d'introduction en bourse de 2009
- Equity Metals a Année d'introduction en bourse de 2009
- Kerr Mines a Année d'introduction en bourse de 2009
- China e-Wallet Payment a Année d'introduction en bourse de 2009
- SQS India BFSI a Année d'introduction en bourse de 2009
- Edesa Biotech a Année d'introduction en bourse de 2010
- Broken Hill Prospecting a Année d'introduction en bourse de 2011
- Apollo Global Management Inc a Année d'introduction en bourse de 2011
- Hipo Resources a Année d'introduction en bourse de 2011
- Cogra 48 SA a Année d'introduction en bourse de 2011
- New Mountain Finance Corp a Année d'introduction en bourse de 2011
- Marfrig Global Foods SA a Année d'introduction en bourse de 2011